Eli Lilly’s weight loss drug tirzepatide, the active ingredient in Zepbound and Mounjaro, has shown remarkable effectiveness in reducing the risk of developing Type 2 diabetes. According to initial results from a long-term study, tirzepatide reduced the risk by 94% in obese or overweight adults with prediabetes, compared to those who received a placebo. The late-stage trial, which lasted approximately three years, also demonstrated sustained weight loss among participants, with those on the highest weekly dose of the drug experiencing an average weight reduction of 22.9% after 176 weeks, in contrast to just 2.1% for the placebo group.
These findings highlight the potential of tirzepatide not only as a weight loss aid but also as a significant preventive measure against Type 2 diabetes for individuals with prediabetes. This condition, characterized by blood sugar levels higher than normal but not yet in the diabetic range, affects more than one-third of Americans, according to recent government data. Health experts note that prediabetes can often be reversed through lifestyle changes, such as improved diet and increased exercise. However, those who are overweight or obese face a higher risk of progressing to Type 2 diabetes.
The study’s results further underscore the long-term health benefits of GLP-1 agonists, a class of medications that include tirzepatide. These drugs mimic gut hormones to suppress appetite and regulate blood sugar, making them effective treatments for both obesity and diabetes. Over the past two years, drugs like Eli Lilly’s Zepbound and Mounjaro, along with similar injections from rival Novo Nordisk, have seen a surge in popularity. In response, pharmaceutical companies have accelerated research to explore additional clinical applications for these medications.
Eli Lilly’s CEO, David Ricks, emphasized the significance of these findings, noting that this is the fourth study this year to demonstrate not only the weight loss benefits of tirzepatide but also its broader health advantages. The drug has shown promise in treating conditions such as heart failure, sleep apnea, and fatty liver disease in other clinical trials.
The phase three trial involved more than 1,000 adults over a 176-week treatment period, followed by a 17-week phase where patients discontinued the drug. This study represents the longest completed research on tirzepatide to date, providing crucial insights into its long-term efficacy and safety.
Eli Lilly’s promising results have not only garnered attention in the medical community but have also positively impacted the company’s stock, which saw a 3% increase following the announcement. The study’s outcomes could lead to broader applications of tirzepatide in preventive health care, particularly for individuals at risk of developing Type 2 diabetes.
READ MORE: